Gasdermin Inhibition Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

• Diseases: [Alzheimer’s disease](/diseases/alzheimers-disease), [Parkinson’s disease](/diseases/parkinsons-disease), ALS, FTD, [Huntington’s disease](/diseases/huntingtons-disease), PSP, MSA

• Brain regions: [substantia nigra](/brain-regions/substantia-nigra), striatum, motor cortex, hippocampus, frontal cortex

• Cell types: [dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), motor neurons, oligodendrocytes

• Proteins/Genes: tau, [alpha-synuclein](/proteins/alpha-synuclein), TDP-43, SNCA, GBA, LRRK2, C9orf72, HTT

• Mechanisms: [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction), [protein aggregation](/mechanisms/protein-aggregation), [oxidative stress](/mechanisms/oxidative-stress), [autophagy](/mechanisms/autophagy), [synaptic dysfunction dysfunction](/mechanisms/synaptic dysfunction-dysfunction)

• Therapeutics: [gene therapy](/therapeutics/gene-therapy-neurodegeneration), ASOs, CRISPR gene editing, deep brain stimulation

• Pathways: complement system, neurotrophic signaling, cell death pathways

Overview

This therapeutic strategy targets gasdermin proteins — the executioners of pyroptosis, a highly inflammatory form of programmed cell death increasingly implicated in neurodegenerative disease progression. Unlike apoptosis, pyroptosis involves gasdermin D (GSDMD) and gasdermin E (GSDME/DFNA5) forming membrane pores that release inflammatory cytokines (IL-1β, IL-18) and alarmins, driving chronic neuroinflammation and neuronal loss. In Alzheimer’s disease, Parkinson’s disease, and ALS, repeated sub-lethal pyroptotic activation creates a self-perpetuating inflammatory loop that accelerates disease progression.^{1Pyroptosis: Gasdermin-mediated programmed necrotic cell death2017 · Trends in Biochemical Sciences · PMID 28196956Open reference2Gasdermin D in neurodegenerative diseases2023 · Cellular and Molecular Neurobiology · PMID 37620247Open reference}

Target

• Primary Target: GSDMD catalytic domain (pore-forming domain) or GSDME^{3Dimethyl fumarate inhibits gasdermin-mediated pyroptosis2022 · Journal of Immunology · PMID 35236891Open reference}

• Target Type: Small-molecule inhibitor, peptide inhibitor, or antibody blocking oligomerization

• Expression: Expressed in microglia, astrocytes, and neurons; upregulated in disease states^{2Gasdermin D in neurodegenerative diseases2023 · Cellular and Molecular Neurobiology · PMID 37620247Open reference}

• Localization: Cytoplasmic protein; active cleaved fragments translocate to plasma membrane

Mechanistic Rationale

Pyroptosis is a highly inflammatory cell death modality distinct from apoptosis. While cGAS-STING inhibition blocks the upstream type I interferon response, gasdermin inhibition blocks a parallel inflammatory axis driven by caspase-1/caspase-4/5 activation:^{1Pyroptosis: Gasdermin-mediated programmed necrotic cell death2017 · Trends in Biochemical Sciences · PMID 28196956Open reference}

1. NLRP3 inflammasome activation: In neurodegeneration, aggregated proteins (amyloid-beta, tau, alpha-synuclein), mitochondrial DAMPs, and damaged mitochondria activate NLRP3 → caspase-1

2. Gasdermin cleavage: Active caspase-1 cleaves GSDMD (and GSDME in some cell types) into N-terminal (pore-forming) and C-terminal (inhibitory) fragments

3. Membrane pore formation: GSDMD-NT oligomerizes at the plasma membrane, forming 10-20nm pores

4. Inflammatory release: IL-1β and IL-18 (pre-formed and activated by caspase-1) are released through pores; cellular swelling leads to lysis

5. Chronic neuroinflammation: Released alarmins (HMGB1, ATP, S100A8/A9) propagate inflammation to neighboring cells

Critically, GSDMD knockout mice show dramatically reduced neuroinflammation in AD and PD models^{4Gasdermin D deficiency attenuates [neuroinflammation](/mechanisms/neuroinflammation) and improves cognitive function in [Alzheimer's disease](/diseases/alzheimers-disease) mouse model2023 · Journal of Neuroinflammation · PMID 36758547Open reference5Targeting GSDMD-mediated pyroptosis for [neuroprotection](/therapeutics/neuroprotection) in [Parkinson's disease](/diseases/parkinsons-disease)2022 · Cell Death & Disease · PMID 36194412Open reference}, making this a high-value target with strong genetic validation.^{4Gasdermin D deficiency attenuates [neuroinflammation](/mechanisms/neuroinflammation) and improves cognitive function in [Alzheimer's disease](/diseases/alzheimers-disease) mouse model2023 · Journal of Neuroinflammation · PMID 36758547Open reference5Targeting GSDMD-mediated pyroptosis for [neuroprotection](/therapeutics/neuroprotection) in [Parkinson's disease](/diseases/parkinsons-disease)2022 · Cell Death & Disease · PMID 36194412Open reference}

flowchart TD
    A["Abeta/Tau/alpha-Syn Aggregates"] --> B["NLRP3 Inflammasome Activation"]
    C["Mitochondrial DAMPs"] --> B
    D["TLR Activation by Pathogen-Associated Patterns"] --> B

    B --> E["Caspase-1 Activation"]
    E --> F["GSDMD Cleavage"]
    E --> G["IL-1beta/IL-18 Processing"]

    F --> H["GSDMD-NT Oligomerization"]
    H --> I["Membrane Pore Formation"]

    G --> J["Cytokine Release via Pores"]
    I --> K["Cell Swelling and Lysis"]
    J --> L["Chronic Neuroinflammation"]
    K --> L

    M["GSDMD Inhibitor"]  -->|"Blocks"| H
    N["Disulfiram"]  -->|"Blocks"| F

    style M fill:#1b5e20,color:white
    style N fill:#1b5e20,color:white
    style L fill:#b71c1c,color:white

Cross-links to relevant mechanisms:

• Pyroptosis in Neurodegeneration

• NLRP3 Inflammasome

• Neuroinflammation

• Inflammasome Activation

• Caspase-1 in Neurodegeneration

• Microglia and Neuroinflammation

• Astrocyte Reactivity

Rubric Score

De-risking Path

1. Phase 1 — Lead identification: Screen FDA-approved drugs (disulfiram, dimethyl fumarate) and natural products for GSDMD inhibition; develop high-throughput GSDMD cleavage assay

2. Phase 2 — Optimization: Medicinal chemistry to improve potency and BBB penetration; structure-activity relationship on disulfiram analogs

3. Phase 3 — Cellular validation: Test in iPSC-derived microglia and neurons exposed to Aβ42, tau, or α-syn; measure IL-1β release, pyroptosis markers, and cell survival

4. Phase 4 — Model efficacy: Test in 5xFAD mice (AD), α-syn pre-formed fibril mice (PD), and SOD1-G93A mice (ALS); measure neuroinflammation and behavioral outcomes

5. Phase 5 — Safety: Chronic toxicology in rodents and non-human primates; assess infection susceptibility during extended dosing

Disease Coverage

Combination Therapy Potential

• With NLRP3 inhibitors (MCC950, dapansutrile): Block upstream inflammasome activation while also inhibiting downstream gasdermin pore formation — dual inhibition for maximum anti-inflammatory effect

• With cGAS-STING inhibitors: Address both DNA-sensing (cGAS-STING) and protein-aggregation-sensing (NLRP3-GSDMD) inflammatory pathways simultaneously

• With anti-aggregation therapies: Reduce inflammatory “fuel” from protein aggregates while blocking the inflammatory response to whatever aggregates remain

Related NeuroWiki Pages

• Pyroptosis in Neurodegeneration | NLRP3 Inflammasome

• Gasdermin Family | GSDMD Protein

• Neuroinflammation | Neuroinflammation Pathway

• Microglia and Neuroinflammation

• Inflammasome Activation

• cGAS-STING Pathway Inhibition — complementary approach

• NLRP3 Senomorphic Cycling — upstream target

Implementation Roadmap

Phase 1: Lead Identification (Months 1-6)

• Objective: Repurpose FDA-approved GSDMD inhibitors

• Activities:

  • Screen approved drugs for GSDMD inhibition (disulfiram, dimethyl fumarate, clomipramine)

  • Develop GSDMD cleavage ELISA for drug screening

  • In vitro potency determination

• Estimated Cost: $500K-1M

• Milestone: 2-3 compounds with micromolar GSDMD inhibition and favorable PK

Phase 2: Optimization & Validation (Months 6-18)

• Objective: Advance leads to preclinical candidates

• Activities:

  • SAR on disulfiram analogs to improve potency and reduce off-target effects

  • BBB penetration optimization

  • iPSC microglia/neuron efficacy testing

• Estimated Cost: $2-3M

• Milestone: Lead compound with nM potency and demonstrated neuroprotection in vitro

Phase 3: Preclinical Development (Months 18-30)

• Objective: GLP toxicology and IND-enabling studies

• Activities:

  • 28-day and 90-day toxicology in rodents

  • PK/PD in AD/PD mouse models

  • Formulation development for oral dosing

• Estimated Cost: $3-5M

• Milestone: IND-ready package with GLP toxicology

Phase 4: Clinical Development (Months 30-48)

• Objective: First-in-human studies

• Activities:

  • Phase 1 dose-escalation in healthy volunteers

  • Phase 2a in early AD or PD patients

  • CSF biomarker validation (IL-1β, GSDMD cleavage products)

• Estimated Cost: $8-15M

• Milestone: Phase 1 safety data and biomarker modulation in patients

Actionable Next Steps

1. Immediate (Week 1-2): Contract research organization to screen FDA-approved drug library for GSDMD inhibition using established cleavage assay^{2Gasdermin D in neurodegenerative diseases2023 · Cellular and Molecular Neurobiology · PMID 37620247Open reference}1

2. Short-term (Month 1-2): Establish iPSC-derived microglia and neuronal cultures from AD/PD patients for in vitro screening

3. Medium-term (Month 2-4): Engage with academic collaborators (e.g.,Dr. Christian Y. Lee, MIT) for access to GSDMD KO mice

4. Partnership (Month 4-8): Identify pharma partner with neuroinflammation franchise for co-development; target companies with existing NLRP3 programs (e.g., Roche, Novartis)

Cross-Links

Related Diseases

• Alzheimer’s Disease — GSDMD-mediated neuroinflammation

• Parkinson’s Disease — α-synuclein-induced pyroptosis

• ALS — TDP-43 and SOD1-driven inflammasome activation

• Frontotemporal Dementia — Tau-driven pyroptosis

Related Mechanisms

• Pyroptosis — Primary therapeutic target

• NLRP3 Inflammasome — Upstream activator of GSDMD

• Neuroinflammation — Downstream consequence

• Inflammasome Activation — Pathway to pyroptosis

• Cell Death Pathways — Comparison with apoptosis and necroptosis

Related Therapeutic Ideas

• cGAS-STING Pathway Inhibition — Complementary neuroinflammation target

• NLRP3 Senomorphic Cycling Therapy — Upstream inflammasome inhibition

• CD38 Inhibition + NAD+ Synergy — Addresses inflammatory metabolism